Kiniksa Pharmaceuticals, Ltd. (KNSA)
NASDAQ$22.61
Market Cap
$1.64B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
666 of 924
Rank in Industry
378 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
KNSA Insider Trading Activity
KNSA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $14,912,940 | 21 | 100 |
Related Transactions
| Megna Michael R | CHIEF ACCOUNTING OFFICER | 0 | $0 | 2 | $203,397 | $-203,397 |
| Moat Ross | CHIEF COMMERCIAL OFFICER | 0 | $0 | 1 | $1.79M | $-1.79M |
| Paolini John F. | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $2.16M | $-2.16M |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | 0 | $0 | 6 | $2.22M | $-2.22M |
| Tessari Eben | CHIEF OPERATING OFFICER | 0 | $0 | 8 | $2.98M | $-2.98M |
| Patel Sanj K | CHAIRMAN & CEO | 0 | $0 | 2 | $5.55M | $-5.55M |
About Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell …
Insider Activity of Kiniksa Pharmaceuticals, Ltd.
Over the last 12 months, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $14.91M worth of Kiniksa Pharmaceuticals, Ltd. stock.
On average, over the past 5 years, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $9.39M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,686,704 shares for transaction amount of $31.99M was made by Flynn James E (10 percent owner) on 2018‑05‑29.
List of Insider Buy and Sell Transactions, Kiniksa Pharmaceuticals, Ltd.
| 2025-03-12 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 9,051 0.0124% | $22.45 | $203,195 | -0.51% | |
| 2025-03-12 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 36,372 0.0495% | $22.25 | $809,277 | -0.51% | |
| 2025-03-10 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 12,409 0.0172% | $21.06 | $261,334 | +7.05% | |
| 2025-02-10 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 14,000 0.0195% | $19.57 | $273,980 | +1.38% | |
| 2025-01-13 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 14,000 0.0197% | $18.24 | $255,413 | +8.59% | |
| 2024-12-16 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 23,017 0.0323% | $20.44 | $470,467 | -1.92% | |
| 2024-12-09 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 18,860 0.0261% | $21.38 | $403,227 | -6.33% | |
| 2024-12-06 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 8,969 0.0123% | $21.27 | $190,771 | -7.02% | |
| 2024-12-05 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 1,123 0.0016% | $21.25 | $23,864 | -4.65% | |
| 2024-12-03 | Sale | Ragosa Mark | CHIEF FINANCIAL OFFICER | 8,969 0.0128% | $21.45 | $192,385 | -5.46% | |
| 2024-11-29 | Sale | Megna Michael R | CHIEF ACCOUNTING OFFICER | 9 <0.0001% | $22.45 | $202 | -9.31% | |
| 2024-11-18 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 17,000 0.023% | $21.04 | $357,680 | -6.23% | |
| 2024-11-06 | Sale | Patel Sanj K | CHAIRMAN & CEO | 89,561 0.1239% | $23.00 | $2.06M | -11.90% | |
| 2024-10-15 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 17,000 0.0268% | $26.87 | $456,790 | -23.47% | |
| 2024-09-23 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 17,500 0.0249% | $24.99 | $437,325 | -13.77% | |
| 2024-09-03 | Sale | Paolini John F. | CHIEF MEDICAL OFFICER | 60,692 0.0855% | $26.12 | $1.58M | -17.70% | |
| 2024-09-03 | Sale | Moat Ross | CHIEF COMMERCIAL OFFICER | 68,506 0.0966% | $26.12 | $1.79M | -17.70% | |
| 2024-08-27 | Sale | Tessari Eben | CHIEF OPERATING OFFICER | 17,500 0.0244% | $26.91 | $470,925 | -20.66% | |
| 2024-07-23 | Sale | Patel Sanj K | CHAIRMAN & CEO | 136,124 0.1877% | $25.65 | $3.49M | -15.10% | |
| 2024-07-23 | Sale | Paolini John F. | CHIEF MEDICAL OFFICER | 22,000 0.0311% | $26.32 | $578,966 | -15.10% |
Total: 62
*Gray background shows transactions not older than one year
Insider Historical Profitability
4.3%
| Patel Sanj K | CHAIRMAN & CEO | 79551 0.1095% | $1.8M | 1 | 11 | |
| BAKER BROS. ADVISORS LP | 2700597 3.7176% | $61.06M | 2 | 0 | +4.3% | |
| Cormorant Asset Management, LP | director | 900443 1.2395% | $20.36M | 1 | 0 | +4.3% |
| Flynn James E | 10 percent owner | 843352 1.1609% | $19.07M | 1 | 0 | +4.3% |
| Beetham Thomas W. | EVP & Chief Legal Officer | 297523 0.4096% | $6.73M | 1 | 6 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.04B | |
$8,217,280 | 112 | 46.33% | $1.29B | |
$831,902,292 | 108 | 9.34% | $1.58B | |
$20,297,544 | 73 | 103.06% | $1.61B | |
$1,101,324,300 | 58 | 37.37% | $1.3B |
KNSA Institutional Investors: Active Positions
| Increased Positions | 79 | +37.26% | 4M | +8.7% |
| Decreased Positions | 95 | -44.81% | 4M | -10.71% |
| New Positions | 20 | New | 353,759 | New |
| Sold Out Positions | 35 | Sold Out | 1M | Sold Out |
| Total Postitions | 196 | -7.55% | 39M | -2.01% |
KNSA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $72,437.00 | 8.5% | 3.57M | -245,393 | -6.43% | 2024-12-31 |
| Braidwell Lp | $70,016.00 | 8.22% | 3.45M | +557,934 | +19.28% | 2024-12-31 |
| Vanguard Group Inc | $65,048.00 | 7.64% | 3.21M | -90,759 | -2.75% | 2024-12-31 |
| Baker Bros. Advisors Lp | $57,156.00 | 6.71% | 2.82M | 0 | 0% | 2024-12-31 |
| Rubric Capital Management Lp | $53,115.00 | 6.24% | 2.62M | +200,000 | +8.27% | 2024-12-31 |
| Fairmount Funds Management Llc | $44,501.00 | 5.23% | 2.19M | -1M | -31.53% | 2024-12-31 |
| Hhlr Advisors, Ltd. | $32,096.00 | 3.77% | 1.58M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $30,172.00 | 3.54% | 1.49M | +462,276 | +45.08% | 2024-12-31 |
| Pictet Asset Management Holding Sa | $22,996.00 | 2.7% | 1.13M | -73,818 | -6.11% | 2024-12-31 |
| Nuveen Asset Management, Llc | $16,135.00 | 1.89% | 795,612 | +54,361 | +7.33% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.